Modifying genes in cystic fibrosis;Les gènes modificateurs dans la mucoviscidose

Medecine Therapeutique Pediatrie

Volumn 8, Issue 3, 2005, Pages 150-155

  Corvol, Harriet ^a   Brouard, Jacques ^a   Clément, Annick ^a  

^a ARMAND TROUSSEAU HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

MANNOSE BINDING LECTIN; NITRIC OXIDE;

ACE GENE; ANTIMICROBIAL ACTIVITY; AUTOSOMAL RECESSIVE INHERITANCE; CAUCASIAN; CFTR GENE; CYSTIC FIBROSIS; DNA MODIFICATION; GENE; GENE EXPRESSION; GENE MUTATION; GENETIC HETEROGENEITY; GENOTYPE PHENOTYPE CORRELATION; GST GENE; HLA GENE; HUMAN; IL 10 GENE; MBL GENE; NO GENE; PATHOGENESIS; REVIEW; TGF BETA GENE; TNF ALPHA GENE;

EID: 27644551927     PISSN: 12865494     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Kerem E, Corey M, Kerem B, Durie P, Tsui LC, Levison H. Clinical and genetic comparisons of patients with cystic fibrosis, with or without meconium ileus. J Pediatr 1989; 114: 767-73.
2. Riordan JR, Rommens JM, Kerem B, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989; 245: 1066-73.
3. Riordan JR. Assembly of Functional CFTR Chloride Channels. Annu Rev Physiol 2004.
4. Jaffe A, Bush A. Cystic fibrosis: review of the decade. Monaldi Arch Chest Dis 2001; 56: 240-7.
5. Lewis MJ, Lewis 3rd EH, Amos JA, Tsongalis GJ. Cystic fibrosis. Am J Clin Pathol 2003; 120(Suppl): S3-S13.
6. Accurso FJ, Sontag MK. Seeking modifier genes in cystic fibrosis. Am J Respir Crit Care Med 2003; 167: 289-90.
7. Acton JD, Wilmott RW. Phenotype of CF and the effects of possible modifier genes. Paediatr Respir Rev 2001; 2: 332-9.
8. Drumm ML. Modifier genes and variation in cystic fibrosis. Respir Res 2001; 2: 125-8.
9. Salvatore F, Scudiero O, Castaldo G. Genotype-phenotype correlation in cystic fibrosis: the role of modifier genes. Am J Med Genet 2002; 111: 88-95.
10. Zielenski J. Genotype and phenotype in cystic fibrosis. Respiration (Herrlisheim) 2000; 67: 117-33.
11. Kerem E, Kerem B. The relationship between genotype and phenotype in cystic fibrosis. Curr Opin Pulm Med 1995; 1: 450-6.
12. Rowntree RK, Harris A. The phenotypic consequences of CFTR mutations. Ann Hum Genet 2003; 67: 471-85.
13. Mekus F, Ballmann M, Bronsveld I, Bijman J, Veeze H, Tummler B. Categories of deltaF508 homozygous cystic fibrosis twin and sibling pairs with distinct phenotypic characteristics. Twin Res 2000; 3: 277-93.
14. Davis PB, Drumm M, Konstan MW. Cystic fibrosis. Am J Respir Crit Care Med 1996; 154: 1229-56.
15. Garred P, Pressler T, Madsen HO, et al. Association of mannose-binding lectin gene heterogeneity with severity of lung disease and survival in cystic fibrosis. J Clin Invest 1999; 104: 431-7.
16. Gabolde M, Guilloud-Bataille M, Feingold J, Besmond C. Association of variant alleles of mannose binding lectin with severity of pulmonary disease in cystic fibrosis: cohort study. BMJ 1999; 319: 1166-7.
17. Davies J, Neth O, Alton E, Klein N, Turner M. Differential binding of man nose-binding lectin to respiratory pathogens in cystic fibrosis. Lancet 2000; 355: 1885-6.
18. Gabolde M, Hubert D, Guilloud-Bataille M, Lenaerts C, Feingold J, Besmond C. The mannose binding lectin gene influences the severity of chronic liver disease in cystic fibrosis. J Med Genet 2001; 38: 310-1.
19. Yarden J, Radojkovic D, De Boeck K, et al. Polymorphisms in the mannose binding lectin gene affect the cystic fibrosis pulmonary phenotype. J Med Genet 2004; 41: 629-33.
20. Grasemann H, Ratjen F. Cystic fibrosis lung disease: the role of nitric oxide. Pediatr Pulmonol 1999; 28: 442-8.
21. Grasemann H, Michler E, Wallot M, Ratjen F. Decreased concentration of exhaled nitric oxide (NO) in patients with cystic fibrosis. Pediatr Pulmonol 1997; 24: 173-7.
22. Grasemann H, Knauer N, Buscher R, Hubner K, Drazen JM, Ratjen F. Airway nitric oxide levels in cystic fibrosis patients are related to a polymorphism in the neuronal nitric oxide synthase gene. Am J Respir Crit Care Med 2000; 162: 2172-6.
23. Grasemann H, Storm van's Gravesande K, Gartig S, et al. Nasal nitric oxide levels in cystic fibrosis patients are associated with a neuronal NO synthase (NOS1) gene polymorphism. Nitric Oxide 2002; 6: 236-41.
24. Grasemann H, van's Gravesande KS, Buscher R, et al. Endothelial nitric oxide synthase variants in cystic fibrosis lung disease. Am J Respir Crit Care Med 2003; 167: 390-4.
25. Texereau J, Marullo S, Hubert D, et al. Nitric oxide synthase 1 as a potential modifier gene of decline in lung function in patients with cystic fibrosis. Thorax 2004; 59: 156-8.
26. Khan TZ, Wagener JS, Bost T, Martinez J, Accurso FJ, Riches DW. Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med 1995; 151: 1075-82.
27. Bonfield TL, Panuska JR, Konstan MW, et al. Inflammatory cytokines in cystic fibrosis lungs. Am J Respir Crit Care Med 1995; 152: 2111-8.
28. Greally P, Hussein MJ, Cook AJ, Sampson AP, Piper PJ, Price JF. Sputum tumour necrosis factor-alpha and leukotriene concentrations in cystic fibrosis. Arch Dis Child 1993; 68: 389-92.
29. Kroeger KM, Carville KS, Abraham LJ. The -308 tumor necrosis factor-alpha promoter polymorphism effects transcription. Mol Immunol 1997; 34: 391-9.
30. Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci USA 1997; 94: 3195-9.
31. Huang SL, Su CH, Chang SC. Tumor necrosis factor-alpha gene polymorphism in chronic bronchitis. Am J Respir Crit Care Med 1997; 156: 1436-9.
32. Hull J, Thomson AH. Contribution of genetic factors other than CFTR to disease severity in cystic fibrosis. Thorax 1998; 53: 1018-21.
33. Arkwright PD, Pravica V, Geraghty PJ, et al. End-organ dysfunction in cystic fibrosis: association with angiotensin I converting enzyme and cytokine gene polymorphisms. Am J Respir Crit Care Med 2003; 167: 384-9.
34. Ohno I, Lea RG, Flanders KC, et al. Eosinophils in chronically inflamed human upper airway tissues express transforming growth factor beta 1 gene (TGF beta 1). J Clin Invest 1992; 89: 1662-8.
35. Nakamura T, Ebihara I, Fukui M, Tomino Y, Koide H. Effect of a specific endothelin receptor A antagonist on mRNA levels for extracellular matrix components and growth factors in diabetic glomeruli. Diabetes 1995; 44: 895-9.
36. Arkwright PD, Laurie S, Super M, et al. TGF-beta(1) genotype and accelerated decline in lung function of patients with cystic fibrosis. Thorax 2000; 55: 459-62.
37. Schurmann M. Angiotensin-converting enzyme gene polymorphisms in patients with pulmonary sarcoidosis: impact on disease severity. Am J Pharmacogenomics 2003; 3: 233-43.
38. Schurmann M, Reichel P, Muller-Myhsok B, et al. Angiotensin-converting enzyme (ACE) gene polymorphisms and familial occurrence of sarcoidosis. J Intern Med 2001; 249: 77-83.
39. Osika E, Cavaillon JM, Chadelat K, et al. Distinct sputum cytokine profiles in cystic fibrosis and other chronic inflammatory airway disease. Eur Respir J 1999; 14: 339-46.
40. Noah TL, Black HR, Cheng PW, Wood RE, Leigh MW. Nasal and bronchoalveolar lavage fluid cytokines in early cystic fibrosis. J Infect Dis 1997; 175: 638-47.
41. Lazarus R, Klimecki WT, Palmer LJ, et al. Single-nucleotidepolymorphisms in the interleukin-10 gene: differences in frequencies, linkage disequilibrium patterns, and haplotypes in three United States ethnic groups. Genomics 2002; 80: 223-8.
42. Brouard J, Knauer N, Boelle PY, et al. Influence of Interleukin-10 on Aspergillus fumigatus infection in patients with cystic fibrosis. J Infect Dis 2005; 191; (Jun 1).
43. Aron Y, Bienvenu T, Hubert D, Dusser D, Dall'Ava J, Polla BS. HLA-DR polymorphism in allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol 1999; 104: 891-2.
44. Aron Y, Swierczewski E, Lockhart A. HLA class II haplotype in atopic asthmatic and non-atopic control subjects. Clin Exp Allergy 1995; 25(Suppl 2): 65-7; (discussion 95-6).
45. Doring G, Krogh-Johansen H, Weidinger S, Hoiby N. Allotypes of alpha 1-antitrypsin in patients with cystic fibrosis, homozygous and heterozygous for deltaF508. Pediatr Pulmonol 1994; 18: 3-7.
46. Mahadeva R, Westerbeek RC, Perry DJ, et al. Alpha1-antitrypsin deficiency alleles and the Taq-I G→A allele in cystic fibrosis lung disease. Fur Respir J 1998; 11: 873-9.
47. Mahadeva R, Sharpies L, Ross-Russell RI, Webb AK, Bilton D, Lomas DA. Association of alpha(1)-antichymotrypsin deficiency with milder lung disease in patients with cystic fibrosis. Thorax 2001; 56: 53-8.
48. Frangolias DD, Ruan J, Wilcox PJ, et al. Alpha 1-antitrypsin deficiency alleles in cystic fibrosis lung disease. Am J Respir Cell Mol Biol 2003; 29: 390-6.
49. Groppi A, Coutelle C, Fleury B, Iron A, Begueret J, Couzigou P. Glutathione S-transferase class mu in French alcoholic cirrhotic patients. Hum Genet 1991; 87: 628-30.
50. Flamant C, Henrion-Caude A, Boelle PY, et al. Glutathione-S-transferase M1, M3, P1 and T1 polymorphisms and severity of lung disease in children with cystic fibrosis. Pharmacogenetics 2004; 14: 295-301.
51. Henrion-Caude A, Flamant C, Roussey M, et al. Liver disease in pediatric patients with cystic fibrosis is associated with glutathione S-transferase P1 polymorphism. Hepatology 2002; 36: 913-7.